Sort
4,870 grants matching “glp 1”
MTR1: A Dinucleotide Substrate Enhancement and Molecular ByPass Therapy for Thymidine Kinase 2 Deficiency
$897,699Ward Peterson · Mitorainbow Therapeutics, Inc. · R44 · FY2023 · GM
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
$896,990Farhad Parhami · Max Biopharma, Inc. · R44 · FY2023 · DK
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
$896,878Anthony D Saleh · Mirecule, Inc. · R44 · FY2025 · CA
Development of Novel Therapeutic Agents for Norovirus Infection
$895,635Kyeong-Ok Chang · Kansas State University · U01 · FY2013 · AI
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease
$895,539Gary Fanger · Rise Therapeutics, Llc · R44 · FY2021 · DK
National Gene Vector Biorepository and Coordinating Center at Indiana University
$893,258Kenneth G Cornetta · Indiana University Indianapolis · P40 · FY2017 · HL
National Gene Vector Biorepository and Coordinating Center at Indiana University
$893,258Kenneth G Cornetta · Indiana University Indianapolis · P40 · FY2016 · HL
Oral Immunotherapy with IgA to Treat C. difficile Infection
$892,325Stephen C Brown · Secretory Iga, Inc. · R44 · FY2022 · DK
A Novel Immunological Probiotic for Treating Inflammatory Bowel Disease
$892,209Gary Fanger · Rise Therapeutics, Llc · R44 · FY2020 · DK
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
$889,701Farhad Parhami · Max Biopharma, Inc. · R44 · FY2024 · DK
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure
$887,140Lawrence Mahan · Madeleine Pharmaceuticals, Inc. · R44 · FY2020 · HL
IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid
$886,552Matthew Ku · O-Ray Pharma, Inc. · R44 · FY2022 · AI
Theranostic for gastric cancer
$885,123Valerie Humblet · Collagen Medical, Llc · R44 · FY2024 · CA
Biobehavioral Studies of Obesity, Weight loss and Recidivism
$884,823Ranganath Muniyappa · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK
Development of a Novel Lead Series Against Category A & B Bacterial Pathogens
$884,280Terry L Bowlin · Microbiotix, Inc · U01 · FY2013 · AI
Development of a High Efficiency Plasma Sterilizer
$880,589Ward A Putnam · Sterilucent, Inc. · R44 · FY2006 · HL
Advancing a Glioma Immunotherapy
$879,408Dwaine Franklin Emerich · In Cytu, Inc. · R44 · FY2016 · NS
CENTER FOR RECOMBINANT GAMETE CONTRACEPTIVE VACCINOGENS
$879,398University Of Virginia Charlottesville · U54 · FY2002 · HD
IND-enabling Preclinical Development of Sustained Release Inner Ear Delivery of Corticosteroid
$879,062Matthew Ku · O-Ray Pharma, Inc. · R44 · FY2023 · AI
Antithrombotic Therapy with No Bleeding Risk for PCI
$878,319Ridong Chen · Apt Therapeutics, Inc. · R44 · FY2018 · HL
Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF
$876,494Gene Leflore Bidwell · Leflore Technologies, Llc · R42 · FY2022 · DK
Pediatric toxicity and efficacy in long-term systemic treatment with anti-sense
$876,181John N Van Den Anker · Children'S Research Institute · U54 · FY2011 · HD
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
$875,832Zhirui Wang · Rock Immune Llc · R42 · FY2023 · CA
Mechanosensitive Channel based Pressure-Modulating Gene Therapy for Glaucoma Treatment
$875,350Adnan Ismail Dibas · Nanoscope Technologies, Llc · R44 · FY2023 · EY
Targeting Irritable Bowel Syndrome (IBS) with astressins
$875,078Dominic Behan · Sentia Medical Sciences, Inc. · R44 · FY2020 · DK